BACKGROUND & AIMS: Guidelines recommend that patients with colon adenomas undergo periodic surveillance colonoscopy. The purpose of this study was to estimate the cost-effectiveness of these recommendations. METHODS: We developed a Markov model to study various surveillance strategies from the perspective of a long-term payer. We modeled a cohort of 50-year-old patients with newly diagnosed adenomas, following them until death. Thirty percent of the population was assumed to be at high risk for colorectal cancer. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured. RESULTS: Performing colonoscopies every 3 years in high-risk patients and every 10 years in low-risk patients (3/10 strategy) was more costly but also more effective than no surveillance, with an ICER of $5,743 per QALY gained. Compared with this 3/10 strategy, a 3/5 strategy was considerably more costly but only marginally more effective, with an ICER of $296,266 per QALY. A 3/3 strategy was more costly and less effective than a 3/5 strategy (dominated). Results were most sensitive to the annual probability of advanced adenoma formation and the relative risk (RR) of advanced adenoma formation in high-risk versus low-risk patients. Assuming that the probability of advanced adenoma formation was 1.3% per year (base: 0.5%), the ICER of the 3/5 strategy was <$50,000 per QALY gained if the RR of advanced adenoma formation was <2.4 (base: 3.9). CONCLUSIONS: Surveillance colonoscopy is cost-effective for patients who are at high risk for developing colorectal cancer. Aggressive surveillance can be expensive or even harmful; efforts should be made to improve risk models for colonic neoplasia. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: Guidelines recommend that patients with colon adenomas undergo periodic surveillance colonoscopy. The purpose of this study was to estimate the cost-effectiveness of these recommendations. METHODS: We developed a Markov model to study various surveillance strategies from the perspective of a long-term payer. We modeled a cohort of 50-year-old patients with newly diagnosed adenomas, following them until death. Thirty percent of the population was assumed to be at high risk for colorectal cancer. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured. RESULTS: Performing colonoscopies every 3 years in high-risk patients and every 10 years in low-risk patients (3/10 strategy) was more costly but also more effective than no surveillance, with an ICER of $5,743 per QALY gained. Compared with this 3/10 strategy, a 3/5 strategy was considerably more costly but only marginally more effective, with an ICER of $296,266 per QALY. A 3/3 strategy was more costly and less effective than a 3/5 strategy (dominated). Results were most sensitive to the annual probability of advanced adenoma formation and the relative risk (RR) of advanced adenoma formation in high-risk versus low-risk patients. Assuming that the probability of advanced adenoma formation was 1.3% per year (base: 0.5%), the ICER of the 3/5 strategy was <$50,000 per QALY gained if the RR of advanced adenoma formation was <2.4 (base: 3.9). CONCLUSIONS: Surveillance colonoscopy is cost-effective for patients who are at high risk for developing colorectal cancer. Aggressive surveillance can be expensive or even harmful; efforts should be made to improve risk models for colonic neoplasia. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee Journal: Epidemiol Rev Date: 2017-01-01 Impact factor: 6.222
Authors: Peter D Siersema; Amit Rastogi; Anke M Leufkens; Paul A Akerman; Kassem Azzouzi; Richard I Rothstein; Frank P Vleggaar; Alessandro Repici; Giacomo Rando; Patrick I Okolo; Olivier Dewit; Ana Ignjatovic; Elizabeth Odstrcil; James East; Pierre H Deprez; Brian P Saunders; Anthony N Kalloo; Bradley Creel; Vikas Singh; Anne Marie Lennon; Daniel C DeMarco Journal: World J Gastroenterol Date: 2012-07-14 Impact factor: 5.742
Authors: Melissa Magrath; Edward Yang; Chul Ahn; Christian A Mayorga; Purva Gopal; Caitlin C Murphy; Samir Gupta; Deepak Agrawal; Ethan A Halm; Eric K Borton; Celette Sugg Skinner; Amit G Singal Journal: J Natl Compr Canc Netw Date: 2018-11 Impact factor: 11.908
Authors: Ben Kahn; Zachary Freeland; Purva Gopal; Deepak Agrawal; Christian A Mayorga; Rozina Mithani; Celette Sugg Skinner; Ethan A Halm; Amit G Singal Journal: Cancer Causes Control Date: 2015-09-16 Impact factor: 2.506
Authors: Amit G Singal; Samir Gupta; Jeffrey Lee; Ethan A Halm; Carolyn M Rutter; Douglas Corley; John Inadomi Journal: Clin Gastroenterol Hepatol Date: 2014-12 Impact factor: 11.382
Authors: Reinier G S Meester; Iris Lansdorp-Vogelaar; Sidney J Winawer; Ann G Zauber; Amy B Knudsen; Uri Ladabaum Journal: Ann Intern Med Date: 2019-09-24 Impact factor: 25.391